Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.29%
As of Tuesday, October 06, Tango Therapeutics, Inc.’s TNGX share price has dipped by 5.29%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 6.22%
As of Tuesday, September 22, Tango Therapeutics, Inc.’s TNGX share price has surged by 6.22%, which has investors questioning if this is right time to sell.Jenna Brashear
Which Is a Better Investment, Alvotech or Tango Therapeutics, Inc. Stock?
Learn more about whether Alvotech or Tango Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.04%
As of Friday, September 18, Tango Therapeutics, Inc.’s TNGX share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 5.10%
As of Thursday, September 17, Tango Therapeutics, Inc.’s TNGX share price has surged by 5.10%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,965.7 | $217.7 | 65% |
|
| Shares Out (Mil) | 149.9 | 53.7 | 71% |
|
| Institutional Ownership | 98.9% | 92.9% | 83% |
|
| Float (Mil) | 120.7 | 41.4 | 64% |
|
| Beta | 1.15 | 0.95 | 68% |
|
| Avg Daily Volume (000s) | 4,031 | 583 | 90% |
|
| Price Change (52-week) |
156.5% | 45.5% | 98% |
|
| Growth | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.0% | 13.2% | 96% |
|
| Net Income (5yr) | (14.3%) | (10.1%) | 26% |
|
| EPS (5yr) | 11.7% | 15.7% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.8% | (15.7%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 13 | 12 | |
| Current EPS | ($0.350) | ($1.397) | ($1.661) | |
| Month Ago EPS | ($0.351) | ($1.396) | ($1.685) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.330) | ($1.294) | ($1.520) | |
| Year/Year Chg | (5.1%) | 59.7% | 115.8% | |
| Financials | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $54 | $37 | 21% |
|
| Net Income (TTM) (Mil) | ($124) | ($44) | 10% |
|
| EPS (TTM) | ($0.915) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($144) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $306 | $2 | 87% |
|
| Long-Term Debt (Q1) (Mil) | $29 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | $3,459 | $175 | 57% |
|
| Valuation | TNGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.87 | 2.11 | 75% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (148.4%) | 66.5% | 2% |
|
| Net Margin | (229.9%) | (74.8%) | 4% |
|
| ROA | (18.9%) | (47.1%) | 21% |
|
| ROE | (21.3%) | (54.1%) | 23% |
|
| Liabilities to Assets | 4.6% | 29.0% | 2% |
|
| F-Score | 4 | 2 | 33% |
|
Tango Therapeutics, Inc. did not pass any screens on 10/19/2026.
